NNIT set out to enable future growth in 2022 and launched strategic initiatives to unlock the Group’s full business potential as a specialized IT consulting business focused on the two core business areas of Life Sciences Solutions and Cloud & Digital Solutions with a strong and consolidated Global Delivery Center and streamlined operations.
NNIT announced the transformative divestment of the Group’s infrastructure business, initiated the carve-out process and continued the efforts to consolidate global delivery capabilities in Q2 2022, which was marked by slower-than-expected sales performance. The temporary suspension of NNIT’s full-year outlook is maintained.
In Q4, we saw continued strong growth within the Life Sciences International business while performance within the Private & Public segment remained weak. Once again, our Winning Solutions strategy gained traction, as it now constitutes 55% of NNIT’s revenue compared to 46% in the same period last year.
In Q3, we saw continued strong growth within the Life Sciences International business, and we strengthened this business further with the addition of SL Controls. Once again, our Winning Solutions strategy gained traction, as it now constitutes 54% of NNIT’s revenue compared to 46% in the same period last year.
In Q2, we saw continued strong growth within the Life Sciences International business, and we strengthened this business further with the addition of SL Controls. Once again, our Winning Solutions strategy gained traction, as it now constitutes 52% of NNIT’s revenue compared to 44% in the same period last year.
In Q1, we experienced continued strong growth within the International Life Sciences business, with Excellis performing to plan. Our Private & Public business started to see positive momentum in relation to the Winning Solutions strategy, which now constitutes 49% of NNIT’s revenue.
The NNIT Group provides a wide range of IT consulting services internationally. In Denmark, where the Group HQ is based, we are one of the leading IT consultancies, servicing both private and public sector customers across all industries. In the rest of Europe, Asia and USA, we are solely focused on companies within life sciences.
Weidekampsgade 14
DK-2300 Copenhagen S
Denmark